Health · Pharma & Biotech · 3 hrs ago

FDA rejects China-developed lung cancer drug ivonescimab

FDA rejects China-developed lung cancer drug ivonescimab

The FDA rejected ivonescimab for US use in certain patients with advanced lung cancer.

The drug was invented by China’s Akeso Biopharma, and Florida-based Summit Therapeutics holds the rights to develop it outside China.

The application covered patients whose cancer had progressed after targeted treatment, and the trial compared the drug plus chemotherapy with chemotherapy alone.

The treatment delayed cancer progression, but regulators said the trial did not show a statistically significant increase in how long patients lived.

Summit argued that slow enrollment affected the survival results and sent regulators additional analyses, but the FDA was not persuaded.

The decision blocks the requested US approval and marks a setback for Summit and a drug seen as a sign of China’s growing role in drug development.

The treatment is also being tested in other cancers, but the decision described here concerns only the lung cancer application.

4 sources

Related

What people are saying

FDA reviewersDrug regulators
does not support the positive benefit-risk profile in support of approval
via STAT